1. GPCR/G Protein Neuronal Signaling Membrane Transporter/Ion Channel
  2. Melanocortin Receptor TRP Channel
  3. Eriodictyol

Eriodictyol  (Synonyms: Huazhongilexone)

Cat. No.: HY-N0637 Purity: 99.55%
Handling Instructions Technical Support

Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases.

For research use only. We do not sell to patients.

CAS No. : 552-58-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Eriodictyol:

Top Publications Citing Use of Products

    Eriodictyol purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Feb 14;23(1):109.  [Abstract]

    The investigation of 48 h IC50 of Eriodictyol against U2OS and MG63 cells. The results showed that the IC50s of U2OS and MG63 cells against Eriodictyol were 27.39 μM and 26.11 μM, respectively.

    Eriodictyol purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Feb 14;23(1):109.  [Abstract]

    Eriodictyol (5 mg/kg) could suppress OS growth in vivo and ferroptosis inhibitors could reverse the tumor-suppressing effects of Eriodictyol.

    Eriodictyol purchased from MedChemExpress. Usage Cited in: Ind Crops Prod. 2025 Dec 11;239:122458.

    EA.hy926 cells were treated with indicated natural compounds, including steppogenin (2), naringenin (11) (10 μM; 20 h), and Eriodictyol (12) (10 μM; 20 h), and cell viability was examined using the MTT assay.

    Eriodictyol purchased from MedChemExpress. Usage Cited in: Ind Crops Prod. 2025 Dec 11;239:122458.

    EA.hy926 cells were scraped with a pipette tip and treated with the indicated inhibitory natural compounds, including steppogenin (2) (10 μM), naringenin (11) (10 μM), and Eriodictyol (12) (10 μM), with or without VEGF (10 ng/mL) for 24 h. Scale bar: 500 μm.

    Eriodictyol purchased from MedChemExpress. Usage Cited in: Ind Crops Prod. 2025 Dec 11;239:122458.

    The tube formation of EA.hy926 cells was examined after 8 h of incubation with the indicated natural compounds, including steppogenin (2) (10 μM), naringenin (11) (10 μM), and Eriodictyol (12) (10 μM), with or without VEGF (10 ng/mL). Scale bar: 200 μm.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases[1][2][3][4][5].

    IC50 & Target

    Human Endogenous Metabolite

     

    RNA Polymerase

     

    Cellular Effect
    Cell Line Type Value Description References
    B16-4A5 IC50
    32 μM
    Compound: 10
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    [PMID: 20189399]
    Col2 EC50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against human Col2 cells
    Cytotoxicity against human Col2 cells
    [PMID: 15043407]
    H9c2 EC50
    25.5 μM
    Compound: 13
    Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
    Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 20932762]
    HUVEC ED50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against HUVEC
    Cytotoxicity against HUVEC
    [PMID: 15043407]
    J774.A1 IC50
    32.8 μg/mL
    Compound: 5
    Cytotoxicity against mouse J774A1 cells after 72 hrs by cell-titer assay
    Cytotoxicity against mouse J774A1 cells after 72 hrs by cell-titer assay
    [PMID: 15679330]
    Jurkat IC50
    14.6 μM
    Compound: Eriodictyol
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    [PMID: 30776692]
    Jurkat IC50
    16.2 μM
    Compound: Eriodictyol
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    [PMID: 30776692]
    KB ED50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    [PMID: 15043407]
    L929 EC50
    4 μM
    Compound: eriodictyol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    [PMID: 9287415]
    L929 EC50
    6 μM
    Compound: eriodictyol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    [PMID: 9287415]
    LNCaP ED50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against human LNCAP cells
    Cytotoxicity against human LNCAP cells
    [PMID: 15043407]
    Lu1 ED50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against human Lu1 cells
    Cytotoxicity against human Lu1 cells
    [PMID: 15043407]
    Peritoneal macrophage IC50
    > 100 μM
    Compound: kp25
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    [PMID: 27955927]
    TERT-RPE1 ED50
    > 1 x 103 nM
    Compound: eryodictiol
    Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
    Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
    [PMID: 15043407]
    THP-1 IC50
    > 10 μM
    Compound: 24
    Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
    Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
    [PMID: 25735399]
    U-937 IC50
    > 100 μM
    Compound: 30, eriodictyol
    Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
    Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
    [PMID: 17158054]
    U-937 IC50
    > 100 μM
    Compound: 30, eriodictyol
    Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
    Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
    [PMID: 17158054]
    U-937 IC50
    > 100 μM
    Compound: 30, eriodictyol
    Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
    Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
    [PMID: 17158054]
    Vero IC50
    36.5 μg/mL
    Compound: 5
    Cytotoxicity against african green monkey Vero cells after 72 hrs by cell-titer assay
    Cytotoxicity against african green monkey Vero cells after 72 hrs by cell-titer assay
    [PMID: 15679330]
    In Vitro

    Eriodictyol inhibits LPS-induced inflammatory cytokine protein production and mRNA expression in C57BL/6 mouse bone marrow-derived macrophages[2].
    Eriodictyol (3-300 nM) acts as a functional TRPV1 antagonist in rat spinal cord synaptosomes, inhibiting capsaicin-induced calcium influx with an IC50 of 44 nM, and does not alter baseline calcium levels on its own[3].
    Eriodictyol (1-300 μM; 30 min) has cell-free antioxidant activity, scavenging ABTS radicals with an IC50 of 1.7 μM[3].
    Eriodictyol (2.5-20 μM; 48 h) dose-dependently inhibits LPS-induced NO production in murine peritoneal macrophages, reducing NO to 31.8 μM at 20 μM over 48 h[4].
    Eriodictyol (2.5-20 μM; 48 h) dose-dependently inhibits lysosomal enzyme activity in murine peritoneal macrophages, with significant suppression at 2.5, 5, 10, and 20 μM over 48 h[4].
    Eriodictyol (6.25-50 μM; 1 h) exhibits dose-dependent cellular antioxidant activity in murine splenocytes and macrophages, with EC50 values of 13 μM and 14 μM, respectively, in the CAA assay[4].
    Eriodictyol (5-20 μM; 24 h) dose-dependently suppresses the production of proinflammatory cytokines TNF-α and IL-8 in high glucose-stimulated rat RGC-5 retinal ganglial cells[5].
    Eriodictyol (5-20 μM; 24 h) dose-dependently represses apoptosis in high glucose-stimulated rat RGC-5 retinal ganglial cells by modulating the expression of pro- and anti-apoptotic proteins[5].
    Eriodictyol (5-20 μM; 24 h) enhances activation of the Nrf2/HO-1 pathway in high glucose-stimulated rat RGC-5 retinal ganglial cells, which is required for its protective effects against oxidative stress, inflammation, and apoptosis[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Eriodictyol (0.1-10 mg/kg; p.o.; daily; 10 days) dose-dependently reduces retinal inflammatory markers (TNF-α, eNOS) and plasma lipid peroxidation in streptozotocin-induced diabetic rats, with the 10 mg/kg dose suppressing blood-retinal barrier breakdown by 40% and lowering retinal VEGF and ICAM-1 levels[1].
    Eriodictyol (30 mg/kg; p.o.; single dose; 2 days prior to LPS exposure) significantly attenuates LPS-induced acute lung injury in female C57BL/6 mice via anti-inflammatory and antioxidative mechanisms, including improved survival, reduced inflammatory cytokine production, and activation of the Nrf2-Trx1 pathway[2].
    Eriodictyol (0.45-13.5 mg/kg; p.o.; single dose; 1 hour before capsaicin injection; 1-30 nmol/site; i.t.; single dose; 15 minutes before capsaicin injection) induces antinociception in intraplantar capsaicin-induced nociception in mice, with a maximal oral inhibition of 49 ± 10% (ID50=2.3 mg/kg) and maximal intrathecal inhibition of 64 ± 4% (ID50=2.2 nmol/site)[3].
    Eriodictyol (4.5 mg/kg; p.o.; single dose; 1 hour before intrathecal capsaicin injection) inhibits intrathecal capsaicin-induced nociception in mice by 71 ± 5%[3].
    Eriodictyol (4.5 mg/kg; p.o.; single dose; 1 hour before nociception testing) fully reverses thermal hyperalgesia and reduces mechanical allodynia by 64 ± 7% in CFA-induced inflammatory pain in mice[3].
    Eriodictyol (4.5 mg/kg; p.o.; single dose; 1 hour before intraplantar capsaicin injection) prevents intraplantar capsaicin-induced spinal oxidative stress in mice by preserving non-protein thiol levels and blocking 3-nitrotyrosine formation[3].
    Eriodictyol (combined with hesperidin and eriocitrin) enhances systemic antioxidant capacity and reduces markers of inflammation and oxidative stress in high-fat diet-fed C57BL/6J mice[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    288.25

    Formula

    C15H12O6

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C1C[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 125 mg/mL (433.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.4692 mL 17.3461 mL 34.6921 mL
    5 mM 0.6938 mL 3.4692 mL 6.9384 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.58 mg/mL (8.95 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.58 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.58 mg/mL (8.95 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.58 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.55%

    References
    Cell Assay
    [2]

    Primary cultures of cortical neurons are prepared from day 17 Sprague-Dawley rat embryos and maintained in Neurobasal A medium supplemented with B27. Experiments are performed 7 days after seeding. Aβ25-35 is dissolved in deionized distilled water at a concentration of 1 mM and incubated at 37°C for 7 days to induce its aggregation. Eriodictyol is added at indicated concentrations (20, 40, 80 μM) 2 h prior to Aβ25-35 treatment. Eriodictyol is dissolved in dimethyl sulfoxide (DMSO) at 64 mM as stock solution and diluted in culture medium before use[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    Eighty female C57BL/6 mice are anesthetized by an intraperitoneal injection of 150 mg/kg ketamine HCl and 65 µg/kg xylazine hydrochloride. E. coli LPS is instilled intratracheally (25 µg in 50 µL sterile saline) during inspiration. The control mice receive PBS instillation, while the Eriodictyol- and vehicle-treated mice receive Eriodictyol (30 mg/kg, dissolved in PBS) and vehicle (PBS), respectively, orally 2 days prior to the induction of ALI. The mice are then sacrificed by an intravenous injection of thiopental 24 h after the induction of ALI. The thorax is opened and the blood is sampled by cardiac puncture. Simultaneously, three bronchoalveolar lavage (BAL) procedures are performed, each using 0.5 mL normal saline. The blood is centrifuged (2,000 × g, for 10 min at 4°C) and the serum is stored for further processing; the survival curve is then depicted using the Kaplan-Meier method[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.4692 mL 17.3461 mL 34.6921 mL 86.7303 mL
    5 mM 0.6938 mL 3.4692 mL 6.9384 mL 17.3461 mL
    10 mM 0.3469 mL 1.7346 mL 3.4692 mL 8.6730 mL
    15 mM 0.2313 mL 1.1564 mL 2.3128 mL 5.7820 mL
    20 mM 0.1735 mL 0.8673 mL 1.7346 mL 4.3365 mL
    25 mM 0.1388 mL 0.6938 mL 1.3877 mL 3.4692 mL
    30 mM 0.1156 mL 0.5782 mL 1.1564 mL 2.8910 mL
    40 mM 0.0867 mL 0.4337 mL 0.8673 mL 2.1683 mL
    50 mM 0.0694 mL 0.3469 mL 0.6938 mL 1.7346 mL
    60 mM 0.0578 mL 0.2891 mL 0.5782 mL 1.4455 mL
    80 mM 0.0434 mL 0.2168 mL 0.4337 mL 1.0841 mL
    100 mM 0.0347 mL 0.1735 mL 0.3469 mL 0.8673 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Eriodictyol
    Cat. No.:
    HY-N0637
    Quantity:
    MCE Japan Authorized Agent: